{
  "title": "Biotin — sole-added-active oral product × Lower HbA1c in adults with type 2 diabetes",
  "criteria_version": "NGM-v3105-SOLE-BIOTIN-T2D-HBA1C-1.0",
  "criteria_date": "2026-10-05",
  "method_sources": [
    {
      "id": "M03",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03",
      "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13",
      "official_principle": "Clearly record the question, eligibility criteria and reasons for changes, and distinguish variations in the intervention.",
      "review_level": "Method principles/editions from 1585 and actual byte-for-byte copies of 5 HTML files reused; no new reading of full methodological texts or execution of an official tool in this work"
    },
    {
      "id": "M04",
      "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04",
      "section": "§4.5, §4.6.1–4.6.3, MECIR C42",
      "official_principle": "Distinguish and link studies and reports, and do not omit a study solely because its outcomes are not reported.",
      "review_level": "Method principles/editions from 1585 and actual byte-for-byte copies of 5 HTML files reused; no new reading of full methodological texts or execution of an official tool in this work"
    },
    {
      "id": "M08",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08",
      "section": "§8.1–8.2.3, Table 8.2.a",
      "official_principle": "Hold the outcome and effect of interest fixed, then assess randomization, deviations, missing data, measurement and selective reporting.",
      "review_level": "Method principles/editions from 1585 and actual byte-for-byte copies of 5 HTML files reused; no new reading of full methodological texts or execution of an official tool in this work"
    },
    {
      "id": "M15",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15",
      "section": "§15.2.4, §15.3.1–15.3.3",
      "official_principle": "Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.",
      "review_level": "Method principles/editions from 1585 and actual byte-for-byte copies of 5 HTML files reused; no new reading of full methodological texts or execution of an official tool in this work"
    },
    {
      "id": "M19",
      "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10",
      "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19",
      "section": "§19.1.2, §19.2.1–19.2.4",
      "official_principle": "Questions about harms may require designs, populations and follow-up different from efficacy questions. Case reports do not establish incidence.",
      "review_level": "Method principles/editions from 1585 and actual byte-for-byte copies of 5 HTML files reused; no new reading of full methodological texts or execution of an official tool in this work"
    }
  ],
  "status_dictionary": {
    "Partly verified": "Some related materials/identity/historical information are available, but gaps remain in direct comparisons, plans, access and harms",
    "Unverified": "The actual materials required for the selected direct comparison could not be verified within the retained scope; this does not mean no effect or 0 studies",
    "Review incomplete": "Comparison against original sources/search was not performed within the authorized scope",
    "Not reported": "A scoped status indicating that the item is not stated in the specific material/section that was read",
    "Inaccessible": "Used only for materials for which access was actually attempted and failed. Not assigned to the clinical materials in this work",
    "Insufficient evidence for this criterion": "Used only when relevant studies within a defined scope have been reviewed and the evidence is insufficient to answer the criterion. Not applied to all items in this work",
    "Not applicable": "The extension requiring clinical events beyond HbA1c does not apply; not a substitute for Unverified",
    "Conflicting information": "The conflict between completer and flowchart denominators in the same report is preserved; no new calculation or correction",
    "Met": "Verification of the stated preservation/boundary, distinction and linkage criteria; not new direct HbA1c efficacy evidence, full-text reading or safety certification"
  },
  "schema_version": "chamgap-public-criteria-1.0",
  "condition_origin": "Chamgap’s own application conditions",
  "requirements": [
    {
      "item_id": "N01",
      "question_type": "Independent claim",
      "question": "Which biotin, population and HbA1c comparison does the question concern?",
      "needed": "Adults with T2D · Oral biotin as the sole addition · Comparator with identical background conditions · Between-group HbA1c result at a prespecified time point",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid combining the ingredient as a whole or all glycemic markers into a single result.",
      "application_exception": "Type 1/gestational/healthy populations, confirmed deficiency correction, topical/injectable routes and concurrent changes in chromium are separate.",
      "criterion": "Link the current original effect wording to the actual inclusion/exclusion boundaries and original pointers.",
      "basis": "Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "For each source, compare the direct comparison results that match this question and the reasons for any mismatch."
    },
    {
      "item_id": "N02",
      "question_type": "Common treatment",
      "question": "Does common metformin treatment exclude a comparison of a sole added ingredient?",
      "needed": "Background treatment in both arms, added ingredients, arm-specific changes/rescue treatment and the actual effect of interest",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Common treatment must be distinguished from active ingredients that change concurrently.",
      "application_exception": "A comparison of biotin as the sole addition is not excluded merely because it is described as concomitant treatment.",
      "criterion": "Distinguish the difference in added ingredients from common treatment and link this distinction to endpoint eligibility.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare results in which only biotin differs under identical background treatment, along with changes in diabetes medications."
    },
    {
      "item_id": "N03",
      "question_type": "Product identity",
      "question": "Are the chemical form, origin and manufacturer of the directly eligible product known?",
      "needed": "Exact chemical form, origin, manufacturer and documentation verifying the active ingredient",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid filling in the identity of an eligible HbA1c regimen with a product from another study.",
      "application_exception": "Naming biotin in the question does not verify the chemical form of the actual preparation.",
      "criterion": "Separate verified values for the directly eligible product from null values and reasons for nonverification.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Obtain and link the original product documentation and manufacturing specifications for the eligible result."
    },
    {
      "item_id": "N04",
      "question_type": "Formulation and quality",
      "question": "Are tablet/capsule form, excipients, brand, batch and purity verified?",
      "needed": "Formulation, excipients, brand, batch/purity and other added active ingredients",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid claiming identical composition and quality based solely on a product name.",
      "application_exception": "Specifications of a combination product are not transferred as verification of a sole-active product.",
      "criterion": "Identify the actual locations verifying the eligible formulation and composition/quality, or mark them as unverified.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare the preparation specifications and batch documentation for the eligible comparison."
    },
    {
      "item_id": "N05",
      "question_type": "Dose",
      "question": "What are the eligible biotin dose, frequency and total exposure?",
      "needed": "Eligible dose/frequency, dietary biotin, concurrent supplements and actual exposure",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid using quantities from adjacent FPG studies or safety cases as an HbA1c regimen.",
      "application_exception": "Do not arbitrarily convert values expressed in mg, µmol and µg at different source locations into mass equivalents.",
      "criterion": "Explain what is verified and what is missing about the actual dose and total exposure linked to the selected result.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; details of dose, duration and effect modification are internally designed",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Link the relevant product, dose, frequency and dietary/supplement records to the eligible result."
    },
    {
      "item_id": "N06",
      "question_type": "Duration and follow-up",
      "question": "Have the treatment duration and HbA1c follow-up time been specified?",
      "needed": "Actual treatment duration, prespecified follow-up time and separate post-discontinuation time point",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid transferring FPG at 4/6 weeks or a combination product at 90 days into the same HbA1c time point.",
      "application_exception": "Do not arbitrarily adopt a common minimum treatment duration.",
      "criterion": "Link the eligible treatment duration and prespecified HbA1c follow-up to the original plan/results.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M04 §4.6.3; internal application; M03 §3.2.1–3.2.4; details of dose, duration and effect modification are internally designed",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare the direct comparison's plan, treatment duration and results at each follow-up time point together."
    },
    {
      "item_id": "N07",
      "question_type": "Actual population",
      "question": "Are confirmed T2D diagnosis, baseline HbA1c and disease duration verified?",
      "needed": "Diagnostic criteria, age, baseline HbA1c, disease duration and population composition",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid filling in the actual baseline status of the eligible sample from the population label alone.",
      "application_exception": "Type 1, gestational and drug-induced diabetes, prediabetes and healthy populations are retained as separate questions.",
      "criterion": "Link the actual eligible population/baseline composition to the unverified items.",
      "basis": "M03 §3.2.1; detailed population criteria are internally designed",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare recruitment, diagnosis, baseline tables and population composition for the eligible result."
    },
    {
      "item_id": "N08",
      "question_type": "Biotin status",
      "question": "Have observations of low biotin been recast as confirmed deficiency correction?",
      "needed": "baseline_biotin, deficiency_assay, deficiency definition and eligible status",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to distinguish blood-level observations, unreported status and treatment of confirmed deficiency.",
      "application_exception": "Unreported status is not presumed normal, and a trial is not described as treating deficiency solely because low levels were observed.",
      "criterion": "Separate the status verified by the original source from the level of diagnosis that remains unverified.",
      "basis": "M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Link the deficiency definition/assay to the direct HbA1c results for each relevant population."
    },
    {
      "item_id": "N09",
      "question_type": "Endpoint definition",
      "question": "Were between-group HbA1c changes distinguished from other glycemic outcomes?",
      "needed": "Prespecified between-group HbA1c change difference in %p, adjusted endpoint contrast and measurement/analysis definitions",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid interpreting FPG/PPG, insulin, HOMA-IR, fructosamine or Hb as HbA1c.",
      "application_exception": "Do not automatically equate an adjusted endpoint contrast with a change difference.",
      "criterion": "Attribute observations to the selected endpoint, unit, time point and analysis.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare the original plan with the change/endpoint estimates in the actual HbA1c tables."
    },
    {
      "item_id": "N10",
      "question_type": "Measurement method",
      "question": "Are the HbA1c assay method and red-cell-related factors verified?",
      "needed": "HbA1c assay, interference, anemia/RBC lifespan, transfusion/Hb variants and renal function",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to distinguish changes in measured values from assay/red-cell conditions.",
      "application_exception": "Biotin interference in specific immunoassays is not generalized to all HbA1c methods.",
      "criterion": "Explain the actual assay method and arm-specific measurement conditions for the selected HbA1c outcome, and what remains unverified.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; design considerations in M19 §19.2.2–19.2.4; detailed confounding records are internally designed",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare the assay principles, validation materials and baseline hematological/renal records for the eligible result."
    },
    {
      "item_id": "N11",
      "question_type": "Direct result",
      "question": "Is there an eligible between-group HbA1c estimate for biotin alone?",
      "needed": "Directly eligible between-group HbA1c effect, follow-up time point, denominator and original result location",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to distinguish the existence of related human studies from obtaining a direct result for this question.",
      "application_exception": "Failure to verify a direct result is not described as an effect of 0 or an absence of human studies worldwide.",
      "criterion": "Link the direct estimate or an explicit gap within the currently verified scope.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.5, §4.6.3; limits on the current material conversion follow the user's scope and internal design; M08 §8.2.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify the between-group effect and its definition/time point in the eligible original result."
    },
    {
      "item_id": "N12",
      "question_type": "Intervals and importance",
      "question": "Can the effect magnitude be interpreted using CI, P and MCID?",
      "needed": "Direct effect, confidence interval, variance, denominator and justified importance threshold",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid equating a P value with clinical importance or precision.",
      "application_exception": "Do not arbitrarily set a minimum sample size, number of trials or numerical HbA1c importance threshold.",
      "criterion": "Distinguish reported direct intervals/importance thresholds from the reasons interpretation is not possible.",
      "basis": "M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M15 §15.3.1–15.3.3; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare the direct result's estimate, CI and basis for the MCID together."
    },
    {
      "item_id": "N13",
      "question_type": "Denominators and analysis",
      "question": "Are the allocation, completion, analysis and ITT/PP denominators linked?",
      "needed": "Direct randomized/completed/analysis n, ITT/PP and reasons for/handling of missing data",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid using allocation or completion counts from another endpoint as HbA1c denominators.",
      "application_exception": "Do not sum n across different reports or arbitrarily reconcile flowchart conflicts.",
      "criterion": "Show the actual denominator and handling for the relevant HbA1c outcome, or mark them as unverified.",
      "basis": "M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "For each eligible result, compare the recruitment→allocation→completion→analysis flow and handling of missing data."
    },
    {
      "item_id": "N14",
      "question_type": "Design and allocation",
      "question": "Are allocation, concealment and baseline balance known for the direct HbA1c result?",
      "needed": "Actual eligible comparison design, randomized/nonrandomized allocation, concealment and baseline balance",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid transferring a description of an adjacent randomized study as verification of the design for the selected HbA1c result.",
      "application_exception": "An unverified design is not labeled as crossover/cluster inapplicability or an automatic failure on bias.",
      "criterion": "Distinguish the verified design information for the selected result from the scope that remains unverified.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M08 §8.1–8.2.3; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare the protocol/allocation documents and baseline tables for the direct comparison."
    },
    {
      "item_id": "N15",
      "question_type": "Adherence and rescue treatment",
      "question": "Are actual adherence, diabetes medication changes, diet and exercise known?",
      "needed": "adherence, background meds, rescue/change, diet/exercise and handling in the analysis",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to separate concurrent changes from biotin's contribution.",
      "application_exception": "Verify the actual effect of interest and the handling methods rather than requiring all changes to be identical.",
      "criterion": "Explain arm-specific concurrent changes and adherence in the eligible comparison, and the gaps.",
      "basis": "M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M08 §8.2.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Link adherence, rescue-treatment and arm-specific change records for the eligible original result."
    },
    {
      "item_id": "N16",
      "question_type": "Planning and selective reporting",
      "question": "Were the planned HbA1c outcome, analysis and time points compared with what was reported?",
      "needed": "Registry record text, history, protocol, SAP, actual results and reasons for changes",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to distinguish a registry shell from verification of the original plan.",
      "application_exception": "Failure to obtain material is not recast as confirmed nonregistration or selective reporting.",
      "criterion": "Identify the locations showing what was actually compared and the plans/time points not compared.",
      "basis": "Data collection/selection principles in M04 §4.5–4.6; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current material conversion follow the user's scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare the eligible candidate's registry history and original plan with the actual results."
    },
    {
      "item_id": "N17",
      "question_type": "Adjacent sole-biotin treatment",
      "question": "Were Maebashi's fasting-glucose findings transferred to HbA1c?",
      "needed": "Maebashi’s actual population, ingredient, comparator, time point and endpoint, and whether a between-group HbA1c result exists",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to distinguish the existence of biotin-only studies from an eligible HbA1c result.",
      "application_exception": "Do not reclassify observations of low circulating biotin or the long-term combination arm as a sole-biotin comparison treating confirmed deficiency.",
      "criterion": "Link the originally retained S01 results to the reason for exclusion from direct evidence.",
      "basis": "M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify S01’s actual HbA1c results/plans during an authorized update."
    },
    {
      "item_id": "N18",
      "question_type": "Baseline values",
      "question": "Is Báez-Saldaña’s baseline glycated hemoglobin a follow-up effect?",
      "needed": "Baseline and follow-up HbA1c; the 28-day comparison; table/analysis definitions",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid misreading baseline characteristics as an estimate of between-group change.",
      "application_exception": "Do not recast enzyme or metabolic markers as between-group HbA1c follow-up results.",
      "criterion": "Distinguish S02’s baseline/other results from the unverified eligible effect.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 §8.2.2, M15 §15.3.1; internal application; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify the HbA1c follow-up contrast, denominator and time point in the original results tables."
    },
    {
      "item_id": "N19",
      "question_type": "Dose correction",
      "question": "Were the location-specific values in the µmol/day erratum preserved?",
      "needed": "Relevant locations in the original text and erratum; the 6.14/61.4/20.5 µmol notations; the relationship between versions",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid creating a new dose by ignoring the erratum or standardizing the values to a single value.",
      "application_exception": "Do not turn unclear locations or units into arbitrary mg conversions or personal prescriptions.",
      "criterion": "Link the location-specific correction notations and remaining identity/interpretation limitations to the original text.",
      "basis": "M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify the original bytes, locations and versions of the original text and erratum, and update each exposure record."
    },
    {
      "item_id": "N20",
      "question_type": "Other endpoints",
      "question": "Are Revilla-Monsalve’s lipid/glucose results HbA1c?",
      "needed": "S04’s actual lipid, FPG and insulin results, and eligible between-group HbA1c results",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid substituting changes in other metabolic markers for the selected endpoint.",
      "application_exception": "Do not establish an endpoint match solely from the 28-day randomized placebo design.",
      "criterion": "Link the other endpoints in the original record to the reason for exclusion from direct HbA1c evidence.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify S04’s original plan/results tables for the presence of eligible HbA1c."
    },
    {
      "item_id": "N21",
      "question_type": "Related add-on therapy",
      "question": "What were the exposure and off-treatment periods in Devi/Ranjani?",
      "needed": "Biotin 5 mg 2 times daily for 4 weeks; 2 weeks off; metformin 500 mg/day for 6 weeks in both arms; actual endpoints",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to preserve this candidate added-ingredient comparison without confusing duration and endpoints.",
      "application_exception": "Do not recast 4 weeks of use as 6 weeks of continuous exposure or HbA1c follow-up.",
      "criterion": "Link the retained exposure, common treatment and off-treatment period to the verified endpoints.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M03 §3.2.1–3.2.4; details on dose, persistence and effect modification are internally designed",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify administration, discontinuation and the presence of HbA1c at each time point in the original plan/results."
    },
    {
      "item_id": "N22",
      "question_type": "Conflicting information",
      "question": "Were the completer analyses by arm and the flowchart’s 60 participants both retained?",
      "needed": "S11 results text/tables: control 28 and biotin 26 participants; flowchart: 60 completers; analysis definitions",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid arbitrarily reconciling the conflicting completion/analysis denominators into the selected HbA1c sample.",
      "application_exception": "Do not read blood-test Hb as HbA1c. Recalculations of the original numbers/changes to the flowchart: 0.",
      "criterion": "Preserve conflicting denominators within the same report and the limits on attributing results/endpoints.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M08 §8.2.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare the original text, flowchart, corrections and analysis specifications to verify the reason for the denominator discrepancy."
    },
    {
      "item_id": "N23",
      "question_type": "Positive and nonsignificant findings",
      "question": "Are week 4 P=.001 and week 6 P=.087 the same result?",
      "needed": "S11 FPG endpoint comparison: time point, whether biotin had been stopped, P, and whether the endpoint was HbA1c",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid selecting only the positive time point or treating nonsignificance as equivalence.",
      "application_exception": "Do not transfer FPG results at different time points to an HbA1c effect or turn nonsignificance into an effect of 0.",
      "criterion": "Retain the differences in results and exposure at the two time points together with the limits on direct attribution.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M15 §15.3.1–15.3.3; internal application; M03 §3.2.1–3.2.4; details on dose, persistence and effect modification are internally designed",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Separately verify the prespecified plan, between-group estimates/intervals at each time point and the effect of discontinuation."
    },
    {
      "item_id": "N24",
      "question_type": "Positive combination-product finding",
      "question": "Were 447 participants and P=.03 used as a biotin-only HbA1c result?",
      "needed": "S05: chromium 600 µg+biotin 2 mg/day for 90 days versus placebo; 447 participants; between-group HbA1c P=.03",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "The positive HbA1c result must be preserved while limiting attribution because another ingredient also changed.",
      "application_exception": "The same background diabetes treatment does not isolate the incremental effects of chromium/biotin individually.",
      "criterion": "Link the combination-product results to the reason for exclusion from sole-biotin evidence.",
      "basis": "M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M03 §3.2.3, M08 §8.2.2–8.2.3; internal application; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Separately verify an eligible HbA1c comparison in which only biotin differs against the same chromium background."
    },
    {
      "item_id": "N25",
      "question_type": "Study families and denominators",
      "question": "Were 348 participants and the active arm’s 226 participants counted as a different study/the total n?",
      "needed": "S05/S08/S13 and review S12: study families; 348=active 226/placebo 122; overlap relationships",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid double-counting original reports, follow-up reports, registries and reviews as replication trials or participants.",
      "application_exception": "Do not convert a possibly shared cohort into either confirmed independence or confirmed complete identity.",
      "criterion": "Distinguish verified families/unconfirmed overlaps and report-specific denominators.",
      "basis": "M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare recruitment, periods and participant links across the relevant reports and registries."
    },
    {
      "item_id": "N26",
      "question_type": "Bibliographic candidate",
      "question": "Were Singer/Geohas’s sample and results verified?",
      "needed": "S09 original text and results tables; actual study linkage to registry S14; sole/combination composition",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to distinguish bibliographic discovery from verification of eligible results.",
      "application_exception": "Do not establish a confirmed shared family or participant count when the registry-number linkage is provisional.",
      "criterion": "Identify the verified title/index and the unverified original results/registry linkage.",
      "basis": "M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare the S09 original text with the S14 history and actual recruitment/results."
    },
    {
      "item_id": "N27",
      "question_type": "Other populations",
      "question": "Were type 1 HbA1c candidates transferred to T2D?",
      "needed": "S10’s actual type1 population, common insulin treatment and extraction level",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid counting human studies in a population different from the question’s population as direct results.",
      "application_exception": "Do not delete data from other populations or use them as evidence that no human studies exist.",
      "criterion": "Link S10’s actual population mismatch to the historical access limitations.",
      "basis": "M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M04 §4.6.3, M15 §15.3.1–15.3.3; status distinctions are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify direct T2D results separately and retain type1 data for a different question."
    },
    {
      "item_id": "N28",
      "question_type": "Registered sole-biotin arm",
      "question": "Was GUTERRING excluded solely because its title mentions a combination?",
      "needed": "NCT05832190’s actual 4 arms, biotin-only arm, population/follow-up HbA1c results and plan",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid omitting a potential biotin-only arm candidate solely on the basis of the title.",
      "application_exception": "Do not claim that an eligible T2D HbA1c result has been verified solely because a biotin-only arm exists.",
      "criterion": "Indicate separately the retention of the registry candidate and the lack of verified direct results.",
      "basis": "M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M03 §3.2.1; detailed population criteria are internally designed; M03 §3.2.2–3.2.3; reverse-direction labeling and adaptations for testing are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design; M08 Table 8.2.a, M04 §4.6.3; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify the registry body/history, population, actual biotin-only arm results and HbA1c time points."
    },
    {
      "item_id": "N29",
      "question_type": "Review and independent replication",
      "question": "Is a review counted as an original trial or independent verification?",
      "needed": "The S12 review’s question, search cutoff, included studies/endpoints and links to original reports",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid counting mixtures of endpoints/ingredients and repeated citations as independent results.",
      "application_exception": "Do not claim to have read the entire review/numeric files this time.",
      "criterion": "Distinguish the review’s role and the family/endpoint differences among its included original studies.",
      "basis": "M04 §4.6.1–4.6.2 distinction between studies and reports; cohort/outcome linkage is an internal application; M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.6.1–4.6.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Compare the review’s inclusion tables with the original reports’ results and the overlap/sole-ingredient boundaries."
    },
    {
      "item_id": "N30",
      "question_type": "Older material",
      "question": "Do the discovery and access failure concerning Coggeshall constitute a negative result?",
      "needed": "S16’s actual original text, population, sole-biotin comparison, HbA1c follow-up and historical failure record",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to distinguish a candidate whose original text was not obtained from no effect.",
      "application_exception": "Do not use metadata_and_failed_full_text to represent a current failed-access action or worldwide study absence.",
      "criterion": "Separate the retained discovery/historical failure from the current unread status and the lack of verified eligible evidence.",
      "basis": "M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify the relevant original text, population and follow-up results during an authorized update."
    },
    {
      "item_id": "N31",
      "question_type": "Search scope",
      "question": "Is the lack of verified direct evidence expressed as 0 studies worldwide?",
      "needed": "The 2026-09-15 original review/search scope, ICTRP failure and scope of this reading of retained material",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to distinguish a bounded gate from complete absence of literature.",
      "application_exception": "The 0 searches this time do not mean 0 studies. Historical selection_log/ZIP references do not constitute current acquisition.",
      "criterion": "Link every expression of absence or lack of verification to its actual scope and date.",
      "basis": "M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify search records, unpublished studies/registries and correction coverage in an authorized update as a separate event."
    },
    {
      "item_id": "N32",
      "question_type": "Assay interference",
      "question": "Was TSH/troponin interference generalized to interference with HbA1c itself?",
      "needed": "NIH/FDA’s specific assays, populations, exposures and time points, with separate verification of the HbA1c assay",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to avoid turning biotin interference into actual glycemic improvement or a risk for every test.",
      "application_exception": "Statements concerning specific TSH/NT-proBNP/troponin tests do not directly establish interference with an HbA1c assay.",
      "criterion": "Separate the assay/exposure scope of the retained safety material from the lack of verification for the selected HbA1c endpoint.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; question-specific outcome adaptations are internally designed; M08 Table 8.2.a, M03 §3.2.4; internal application; M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; detailed distinctions are internally designed; M19 §19.2 design-specific harm questions; temporal-relationship details are internally designed; Chamgap’s own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Separately verify validation for each relevant HbA1c method and data on biotin exposure/blood-sampling time points."
    },
    {
      "item_id": "N33",
      "question_type": "Related adverse events",
      "question": "Are the frequencies of nausea, loose stools and gastric irritation in S11 known?",
      "needed": "People with AE/events by arm; collection; exposure/follow-up; safety-analysis denominators; discontinuation",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Needed to distinguish the presence of symptoms from incidence rates or a guarantee of long-term safety.",
      "application_exception": "Do not calculate event rates or NNH from unclear safety denominators, or treat unreported data as 0.",
      "criterion": "Link the retained symptoms to gaps in safety denominators/directly eligible exposure.",
      "basis": "M08 Table 8.2.a, M15 §15.3, M19 §19.1.2–19.2.4; design-specific adaptations are internally designed; M19 §19.1.2–19.2.4; internal application; M19 §19.1.2–19.2.4; detailed distinctions are internally designed; M19 §19.2.2–19.2.4 design considerations; detailed confounding records are internally designed; M19 §19.1.2–19.2.4, M04 §4.6.3; internal application; Chamgap’s own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Separately verify the original AE tables, collection methods and arm-specific denominators/discontinuations."
    },
    {
      "item_id": "N34",
      "question_type": "Long-term use and vulnerable groups",
      "question": "Is there safety evidence for long-term use, pregnancy/lactation, children, hepatic/renal disease and concurrent use?",
      "needed": "Long-term AE and discontinuations by eligible dose; population-specific exposure/interactions and denominators",
      "role": "Supplementary; required for the corresponding extended claims about long-term or special-population safety",
      "role_reason": "Needed to avoid guaranteeing safety in all populations from some brief observations.",
      "application_exception": "Do not unconditionally require every rare-harm study for the current narrow HbA1c question.",
      "criterion": "Distinguish direct information in the same population/exposure from unverified extensions.",
      "basis": "M19 §19.1.2–19.2.4; internal application; Chamgap’s own interpretation boundaries. M19 principles are referenced; no formal causality tool was applied",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Separately verify long-term/population-specific harms and observation conditions for the same product and dose."
    },
    {
      "item_id": "N35",
      "question_type": "Independence and funding",
      "question": "Is the actual scope of funding, product provision and COI known?",
      "needed": "Report-specific funding, product provision, author relationships, COI declarations and original verification locations",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Required to avoid treating unverified funding as absent or as certification of independence.",
      "application_exception": "Do not automatically exclude a study or judge it free of bias solely on historical wording stating the presence or absence of COI.",
      "criterion": "Distinguish the level of disclosures/funding actually verified from materials not read in this review.",
      "basis": "Chamgap’s own independence and attribution criteria. The official methodological sections used in this pilot do not warrant all these detailed items; the distinction between studies and reports in M04 §4.6.1–4.6.2; cohort/outcome linkage is an internal application.",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Verify original research funding/COI and product supply records by report."
    },
    {
      "item_id": "N36",
      "question_type": "Reading level",
      "question": "Have historical full-text access and current summary reading been separated?",
      "needed": "Historical access_level/location by report; actual access dates; current local locations/values/SHA; external access unattempted",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Required to avoid retroactively treating retained statements of PDF access as full-text reading in this review.",
      "application_exception": "If a report has no date field, leave it null; the global verified_date is a separate review date.",
      "criterion": "Link reading badges to the actual retained citations and keep unread external materials separate.",
      "basis": "M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "If new access is separately authorized, independently record the material/time/original bytes."
    },
    {
      "item_id": "N37",
      "question_type": "Original gate and score",
      "question": "Have ?/null values and no_human_study=true been preserved unchanged?",
      "needed": "Original ?/null score; B/S; nulls on the subsequent 5 axes; bounded human scope; related studies true",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Required to avoid treating the historical calculator gate as absence of all human studies or as a new efficacy grade.",
      "application_exception": "Do not alter the original false/true/null values for convenience or convert them to a score of 0 or a new criterion-fulfillment rate.",
      "criterion": "Separate the scope expressed by the original verdict/gate from the statuses of the new criteria.",
      "basis": "Question-clarification principles in M03 §3.1, §3.2.1–3.2.4; detailed separation rules are internally designed; M04 §4.5, §4.6.3; the limits of the current data conversion follow the user’s scope and internal design; M08 §8.2.2, M15 §15.3.1; internal application",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "If direct evidence is added, consider a separate update that preserves the original values/reasons for change."
    },
    {
      "item_id": "N38",
      "question_type": "Technical and deployment metadata",
      "question": "Have server_deployed and actual deployment in this work been distinguished?",
      "needed": "Original server_deployed/server_write_performed/first_published_scope; current local preparation",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Required to avoid treating historical deployment metadata as evidence of site publication in this work.",
      "application_exception": "Do not arbitrarily reconcile the original server_deployed=true and server_write=false.",
      "criterion": "Separate the original metadata values/scope from the current local conversion and absence of public deployment.",
      "basis": "M04 §4.5–4.6 data collection/selection principles; separation of access from reading and the hyperlink contract are internally designed; M04 §4.5, §4.6.3; limits on the current data conversion derive from the user-defined scope and internal design",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "If actual publication is separately authorized, verify the production URL/display/links and record the event."
    },
    {
      "item_id": "N39",
      "question_type": "Boundaries for extensions",
      "question": "Does the HbA1c table also answer questions about clinical events and improvements in quality of life?",
      "needed": "Boundary between the selected HbA1c question and separate questions about complications, quality of life, mortality, duration/dose",
      "role": "Supplementary; required for extended claims about clinical events, duration and dose",
      "role_reason": "Required to avoid extending a numerical surrogate outcome to benefits in clinical events.",
      "application_exception": "Do not make clinical-event trials an unconditional requirement for the numerical HbA1c question.",
      "criterion": "Separate the directly selected endpoint from additional questions extending beyond it.",
      "basis": "M03 §3.2.4, M15 §15.3.1–15.3.3; adapting outcomes to each question is internally designed; M03 §3.2.1–3.2.4; details concerning dose, duration and effect modification are internally designed; M03 §3.2.4; internal boundaries for extensions",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Review direct results and criteria separately for questions about events/long-term outcomes/dose."
    },
    {
      "item_id": "N40",
      "question_type": "Updating and tracking",
      "question": "What changes when new direct results, full texts or corrections are acquired?",
      "needed": "Original identity/dates; original values before/after; corrections/retractions; criterion versions; update links",
      "role": "Required (selected sole-added-biotin/HbA1c comparison)",
      "role_reason": "Required to avoid making the current table a fixed truth or an automatic efficacy upgrade.",
      "application_exception": "Adding new materials is separate from amending criteria/reaching a new verdict and from deployment; do not exceed the current authorized scope.",
      "criterion": "Explicitly link update triggers, required materials and affected items/preservation of history.",
      "basis": "M04 §4.6.3, M15 §15.3.1–15.3.3; separation of statuses is internally designed; M04 §4.5, §4.6.3; the limits of the current data conversion follow the user’s scope and internal design",
      "condition_origin": "Disclosed development conditions designed after reading the current 3105 retained materials; not blinded, clinically preregistered or independently clinically certified",
      "proposed_research": "Register separately authorized full texts, direct HbA1c results and corrections with their exact locations/values/hashes, then review the linked items again."
    }
  ],
  "language": "en",
  "translation_date": "2026-11-03"
}